Cannabis Derivative Sativex 'Shows Promise In US Patients' Despite Further Phase III Failure

'No surprise' apparently, as GW Pharmaceuticals and Otsuka Pharmaceutical Development & Commercialization, Inc. report negative top-line results from the remaining two Phase III trials of their cannabis extract product Sativex (nabiximols) for the treatment of pain in advanced cancer patients who experience inadequate analgesia during optimized chronic opioid therapy.